Carcinogens

Supreme Court's Denial of J&J Petition a 'Victory for Justice'

Retrieved on: 
Tuesday, June 1, 2021
Minerals, Crystallography, Fictional characters, Occupational safety and health, Asbestos, Carcinogens, Talc, Certiorari, General Grievous, Johnson & Johnson

"This decision sends a clear message to everyone: you will be held to account when you cause grievous harm under our system of equal justice under law."

Key Points: 
  • "This decision sends a clear message to everyone: you will be held to account when you cause grievous harm under our system of equal justice under law."
  • The 22 claimants had used the talc-based powders daily for many years, unaware that the products contained asbestos.
  • Several of the women died from the disease prior to the trial, while others have died in the intervening years.
  • The Missouri Supreme Court refused to further consider the appeal by J&J, leading to the filing of the certiorari petition by the company earlier this year.

Center for Asbestos Related Disease (CARD) Is Now Open with Facility Safety Upgrades

Retrieved on: 
Wednesday, May 26, 2021
Asbestos, Minerals, Occupational safety and health, Health, Industrial Minerals, Carcinogens, Tremolite, Lung cancer, Cancer, Health impact of asbestos, Asbestos and the law

LIBBY, Mont., May 26, 2021 /PRNewswire/ -- The Center for Asbestos Related Disease (CARD) is open at full capacity and ready to welcome patients, both for asbestos related disease screening and ongoing care for those already diagnosed.

Key Points: 
  • LIBBY, Mont., May 26, 2021 /PRNewswire/ -- The Center for Asbestos Related Disease (CARD) is open at full capacity and ready to welcome patients, both for asbestos related disease screening and ongoing care for those already diagnosed.
  • One important update is that CARD's Pulmonary Function Labs (PFT) are now open again after a brief closure due to COVID-19.
  • They will continue to provide asbestos related disease screening, lung cancer screening, and ongoing care for those diagnosed with asbestos related disease, as well as educational and outreach opportunities.
  • The Center for Asbestos Related Disease (CARD) has emerged as a national center of excellence in addressing healthcare issues associated with Libby Amphibole (previously called tremolite) asbestos.

PDS Biotech to Host Company Conference Call Following Oral Presentation of PDS0101 Data at 2021 ASCO Annual Meeting

Retrieved on: 
Monday, May 24, 2021
Cancer, Infectious causes of cancer, Papillomavirus, Carcinogenesis, Carcinogens, Human papillomavirus infection, National Cancer Institute

During the call, PSD Biotech will review data from the previously announced oral presentation from the National Cancer Institute (NCI)-led phase 2 trial of PDS0101 in triple combination for the treatment of advanced HPV-associated cancers.

Key Points: 
  • During the call, PSD Biotech will review data from the previously announced oral presentation from the National Cancer Institute (NCI)-led phase 2 trial of PDS0101 in triple combination for the treatment of advanced HPV-associated cancers.
  • Following the presentation, PDS Biotech will hold a question-and-answer session.
  • The conference call is scheduled to begin at 8:00 am ET on Tuesday, June 8, 2021.
  • A copy of PDS Biotech's presentation will be available on June 8th on the scientific presentations and publications page of PDS Biotech's website.

HOOKIPA to present Phase 1 safety, tolerability and preliminary anti-tumor activity data on HB-201 and HB-202 for the treatment of advanced HPV16+ cancers at ASCO

Retrieved on: 
Thursday, May 20, 2021
Infectious causes of cancer, Papillomavirus, Carcinogenesis, Carcinogens, Human papillomavirus infection, Oncology, Papillomaviridae, Medical specialties, Clinical medicine, Biology

HB-201 and HB-202, novel arenaviral therapeutics and HOOKIPA\xe2\x80\x99s lead oncology candidates, are being evaluated in an ongoing, first-in-human Phase 1/2 clinical trial (NCT04180215) for the treatment of advanced Human Papillomavirus 16-positive (HPV16+) cancers.

Key Points: 
  • HB-201 and HB-202, novel arenaviral therapeutics and HOOKIPA\xe2\x80\x99s lead oncology candidates, are being evaluated in an ongoing, first-in-human Phase 1/2 clinical trial (NCT04180215) for the treatment of advanced Human Papillomavirus 16-positive (HPV16+) cancers.
  • Joern Aldag, Chief Executive Officer, and Igor Matushansky, Chief Medical Officer, will provide an overview of the ASCO oral data and future plans for HOOKIPA\xe2\x80\x99s oncology program.
  • The primary endpoint of the Phase 1 is a recommended Phase 2 dose based on safety and tolerability.
  • It is possible that the information we post on social media could be deemed to be material information.

Rubius Therapeutics to Present Trials in Progress Poster on the Phase 1 Clinical Trial of RTX-321 for HPV 16-Positive Cancers at the 2021 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Papillomavirus, Infectious causes of cancer, Carcinogenesis, Carcinogens, Human papillomavirus infection, Forward-looking statement, Medical specialties, Clinical medicine, Articles

A critical need remains for better treatment options for advanced HPV 16-associated cancers.

Key Points: 
  • A critical need remains for better treatment options for advanced HPV 16-associated cancers.
  • The purpose of the trial is to determine the safety and tolerability, recommended Phase 2 dose and pharmacology, and antitumor activity of RTX-321.
  • We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.
  • We explicitly disclaim any obligation to update any forward-looking statements.\n'

SQZ Biotechnologies to Present First Clinical Data at the American Society of Clinical Oncology Annual Meeting from Ongoing Phase 1 Study in Patients with Advanced or Metastatic HPV+ Tumors

Retrieved on: 
Wednesday, May 19, 2021
Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer, Clinical medicine, Medicine, Papillomavirus, Infectious causes of cancer, Carcinogenesis, Carcinogens, Human papillomavirus infection, Checkpoint inhibitor, Cancer immunotherapy, Human Papillomavirus Positive Cancers, SQZ Biotechnologies, HUMAN PAPILLOMAVIRUS POSITIVE CANCERS, SQZ BIOTECHNOLOGIES

In the next stage of the trial, it is planned to combine SQZ-PBMC-HPV-101 with immune checkpoint inhibitors.

Key Points: 
  • In the next stage of the trial, it is planned to combine SQZ-PBMC-HPV-101 with immune checkpoint inhibitors.
  • The study\xe2\x80\x99s primary outcome measures in the monotherapy stage of the trial are safety, tolerability, and the definition of the recommended phase 2 dose.
  • The investigational candidate, which targets E6 and E7 oncoproteins, is being studied as a monotherapy and in combination with immuno-oncology agents.
  • The planned safety combination phase of the study will include SQZ-PBMC-HPV-101 and checkpoint inhibitors that have previously received regulatory approval.

Multiple Chemical Sensitivity Awareness Month: Citizens for Radioactive Radon Reduction's Medical Issue Highlights Pre- and Post-COVID19 Fractured Health of Communities

Retrieved on: 
Friday, May 14, 2021
Physical sciences, Chemistry, Chemical elements, Natural sciences, Carcinogens, Soil contamination, Radon, Cancer, Radium, Radioactive decay

They indicate things such as the beginning and end of a trail, a change of direction, or an intersection.

Key Points: 
  • They indicate things such as the beginning and end of a trail, a change of direction, or an intersection.
  • Future cancer outcomes will be dependent upon individual journeys and markers we leave behind.
  • Traveling through the pandemic provided greater knowledge of what it takes to survive and how important healthy living is to our entire existence.
  • The pandemic effect has brought about a new way of thinking about our life choices.\nDuring "Multiple Chemical Sensitivity Awareness Month," Citizens for Radioactive Radon Reduction (CR3) dedicated its medical issue to "Surviving."

Rubius Therapeutics Announces Publication of RTX-321 Preclinical Data in Nature Communications

Retrieved on: 
Wednesday, May 12, 2021
Papillomavirus, Infectious causes of cancer, Carcinogenesis, Carcinogens, Human papillomavirus infection, Medical specialties, Clinical medicine, Health

Our publication describes an elegant mechanism of action for RTX-321, combining antigen-specific responses with the addition of broad immune stimulation,\xe2\x80\x9d said Laurence Turka, M.D., chief scientific officer of Rubius Therapeutics.

Key Points: 
  • Our publication describes an elegant mechanism of action for RTX-321, combining antigen-specific responses with the addition of broad immune stimulation,\xe2\x80\x9d said Laurence Turka, M.D., chief scientific officer of Rubius Therapeutics.
  • A critical need remains for better treatment options for advanced HPV 16-associated cancers.
  • The purpose of the trial is to determine the safety and tolerability, recommended Phase 2 dose and pharmacology, and antitumor activity of RTX-321.
  • We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.

Health Monitor Wins Top International Creative Awards

Retrieved on: 
Tuesday, May 4, 2021
Infectious causes of cancer, Papillomavirus, Articles, Carcinogenesis, Carcinogens, Human papillomavirus infection, Health, Clinical medicine, Medical specialties

b'MONTVALE, N.J., May 4, 2021 /PRNewswire/ -- Health Monitor Network, a leading provider of integrated marketing solutions that maximize biopharmaceutical/OTC brand growth and improve health outcomes, today announced that they have won a series of top awards in the preeminent Hermes Creative Awards competition.

Key Points: 
  • b'MONTVALE, N.J., May 4, 2021 /PRNewswire/ -- Health Monitor Network, a leading provider of integrated marketing solutions that maximize biopharmaceutical/OTC brand growth and improve health outcomes, today announced that they have won a series of top awards in the preeminent Hermes Creative Awards competition.
  • The company received numerous platinum and gold awards for their groundbreaking work in direct-to-patient marketing at the point of care.
  • Their award-winning digital and print educational materials have impacted millions of patients suffering from conditions such as diabetes, HPV, IBD, severe asthma, heart attack, stroke, and dermatologic conditions.
  • We hope our contentwhich is validated by leading key opinion leaders and medical associationsis making a difference in people\'s everyday lives.

Hemp Over Tobacco: Greene's Reserve Creates Massive Growth

Retrieved on: 
Tuesday, May 4, 2021
Psychoactive drugs, Tobacco, Smoking, Nicotinic agonists, Draft:Full Spectrum Hemp Snuff, Carcinogens, Herbs, Smokeless tobacco, Snuff, Hemp, Nicotine

Greene\'s Reserve has created a proprietary formula that replaces the tobacco with American-grown hemp.\nGreene\'s Reserve\'s Full Spectrum Hemp Snuff has zero nicotine or carcinogens.

Key Points: 
  • Greene\'s Reserve has created a proprietary formula that replaces the tobacco with American-grown hemp.\nGreene\'s Reserve\'s Full Spectrum Hemp Snuff has zero nicotine or carcinogens.
  • "Moreover, users may benefit from all the natural compounds of the hemp plant while kicking tobacco to the curb.
  • Greene\'s Reserve was founded by Jeff Greene, a seasoned hemp and CBD expert native to South Florida.
  • For more information, visit www.greenesreserve.com .\nGreene\'s Reserve, Inc. is a hemp company that manufactures full spectrum snuff as a healthy alternative to smokeless tobacco.